Immune Design Announces Presentations at the 2017 ASCO Annual Meeting
April 20 2017 - 11:01AM
Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company
focused on oncology, today announced that new and updated data from
two ongoing clinical trials of CMB305 and G100, as well as
translational data examining the association of immunological
response with improved survival in CMB305 and LV305 patients, will
be presented in an oral and two posters presentations at the 2017
American Society of Clinical Oncology (ASCO) Annual Meeting, June 2
- 6, 2017 in Chicago. The ASCO presentation details are as follows:
ORAL PRESENTATION
Immune response, safety, and survival impact from CMB305
in NY-ESO-1+ recurrent soft tissue sarcomas (STS)
Abstract
# 11006 |
Session
Title: Sarcoma |
Date:
Friday, June 2, 2017 |
Time: 3
p.m. – 6 p.m. CT (oral session) |
Location:
S100bc |
Presenter: Neeta Somaiah, M.D., Department of Sarcoma Medical
Oncology, The University of Texas MD Anderson Cancer Center |
POSTER PRESENTATIONS
The Association of CMB305 or LV305-induced and baseline
anti-NY-ESO-1 immunity with survival in recurrent cancer
patients
Abstract
# 3090 |
Session
Title: Developmental Therapeutics—Immunotherapy |
Date:
Monday, June 5, 2017 |
Time: 8
a.m. – 11:30 a.m. CT (poster session) |
Location:
Hall A |
Presenter: Seth M. Pollack, M.D., Fred Hutchinson Cancer Research
Center |
Intratumoral G100 to induce systemic immune responses
and abscopal tumor regression in patients with follicular
lymphoma
Abstract
# 7537 |
Session
Title: Hematologic Malignancies – Lymphoma and Chronic Lymphocytic
Leukemia |
Date:
Monday, June 5, 2017 |
Time: 8
a.m. – 11:30 a.m. CT (poster session) |
Location:
Hall A |
Presenter: Christopher Flowers, M.D., Department of Hematology and
Medical Oncology, Emory University School of Medicine |
Additional data than those included in the abstracts may be
included in the presentations.
About Immune Design
Immune Design is a clinical-stage immunotherapy
company employing next-generation in vivo approaches to
enable the body's immune system to fight disease. The company's
technologies are engineered to activate the immune system's natural
ability to generate and/or expand antigen-specific cytotoxic T
cells, while also enhancing other immune effectors, to fight cancer
and other chronic diseases. CMB305 and G100, the primary foci
of Immune Design's ongoing immuno-oncology clinical programs, are
products of its two synergistic discovery platforms, ZVex and
GLAAS, the fundamental technologies of which were licensed from the
California Institute of Technology and the Infectious Disease
Research Institute (IDRI), respectively. Immune Design has
offices in Seattle and South San Francisco. For more information,
please visit www.immunedesign.com.
Cautionary Note on Forward-Looking
Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Words such as "may," "will," "expect," "plan,"
"anticipate," "estimate," "intend" and similar expressions (as well
as other words or expressions referencing future events, conditions
or circumstances) are intended to identify forward-looking
statements. These forward-looking statements are based
on Immune Design's expectations and assumptions as of the
date of this press release. Each of these forward-looking
statements involves risks and uncertainties. Factors that may
cause Immune Design's actual results to differ from those
expressed or implied in the forward-looking statements in this
press release are discussed in Immune Design's filings
with the U.S. Securities and Exchange Commission, including
the "Risk Factors" sections contained therein. Except as required
by law, Immune Design assumes no obligation to update any
forward-looking statements contained herein to reflect any change
in expectations, even as new information becomes available.
Media Contact
Julie Rathbun
Rathbun Communications
julie@rathbuncomm.com
206-769-9219
Investor Contact
Shari Annes
Annes Associates
sannes@annesassociates.com
650-888-0902
IMMUNE DESIGN CORP. (NASDAQ:IMDZ)
Historical Stock Chart
From Mar 2024 to Apr 2024
IMMUNE DESIGN CORP. (NASDAQ:IMDZ)
Historical Stock Chart
From Apr 2023 to Apr 2024